Skip to content
Screener

ADMA Biologics ADMA Price / earnings

Price / earnings at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
1.2×—
AbbVie logo
AbbVieABBV
70.5×-16.6×
Charles River Laboratories logo
Charles River LaboratoriesCRL
24×+2.8×
Haemonetics logo
HaemoneticsHAE
21.4×-8.8×
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
44.6×—

Other financials

Income statement

See full
Revenue$124.4M+2.0%
Gross profit$86.3M+28.3%
Operating income$52.4M+22.5%
Net income$37.8M+10.5%
EPS (diluted)$0.16+14.3%

Balance sheet

See full
Cash & equivalents$136.0M+50.7%
Total debt$203.9M+1,855%
Total equity$408.2M+2.5%
Total assets$684.2M+22.5%

Cash flow

See full
Operating cash flow$29.5M+39.7%
CapEx$2.3M-6.9%
Free cash flow$27.3M+45.8%

Valuation

See full
Market cap$2.25B-49.1%
Enterprise value$2.32B-46.6%
P/S4.4×-4.9×

Profitability

See full
Gross margin64.7%+11.7pp
Operating margin43.8%+11.0pp
Net margin33%-11.1pp
FCF margin22.7%+8.9pp

Returns & leverage

See full
Return on equity41.9%-29.3pp
Debt / equity0.5×+0.5×
Current ratio7×+1.6×

Where this comes from

Calculated from ADMA Biologics’s reported figures.

market cap/net income=11.5×

Based on the most recent quarter.

The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 5:16 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001140361-26-031445

FAQ

What is ADMA Biologics's price / earnings?
ADMA Biologics (ADMA) reported price / earnings of 11.5× in Q2 2026.
How has ADMA Biologics's price / earnings changed year-over-year?
ADMA Biologics's price / earnings decreased by 43.7% year-over-year, from 20.4× to 11.5×.
What does price / earnings mean?
Market capitalization at the quarter end divided by trailing-twelve-month net income. The price the market pays for each dollar of trailing earnings.

Ask your AI about ADMA Biologics's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude